US Pre-Market SEC Filings Roundup — January 11, 2026

12-01-2026

Kura Oncology, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009649), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a multi-item filing focused on financial results.

12-01-2026

Tempus AI, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009650, size 174 KB) disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction values, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001187, Size: 225 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financial impacts provided in the summary. Sector not specified.

12-01-2026

IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009641, Size: 4 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, financial metrics, transaction values, or exhibit contents are explicitly stated in the provided filing summary. Sector is not specified.

12-01-2026

Veracyte, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001384101-26-000002, Size: 186 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure event. No specific revenue, earnings, transaction values, or other quantitative metrics are disclosed in the provided filing summary.

12-01-2026

Jaguar Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009644), disclosing under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, and Item 3.02 unregistered sales of equity securities. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, or quantitative metrics are provided in the filing summary.

12-01-2026

Guardant Health, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001576280-26-000004, Size: 202 KB), disclosing Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This is a financial results announcement typical for quarterly earnings releases. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Terra Property Trust, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002583, Size: 198 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

MBX Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009642, Size: 263 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific numerical data, transaction details, or financial metrics are disclosed in the provided information.

12-01-2026

Thermo Fisher Scientific Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000871, Size: 310 KB), disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements. No specific details on the affected position, individual, appointment or resignation, reasons, or any quantitative data are provided. Sector is not specified.

12-01-2026

TEVA PHARMACEUTICAL INDUSTRIES LTD filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000174, Size: 244 KB), reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a multi-item filing related to financial results.

12-01-2026

Cracker Barrel Old Country Store, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002590, Size: 2 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, financial data, transactions, or exhibits are disclosed in the provided filing summary. This is a multi-item filing with voluntary disclosure elements under Regulation FD.

12-01-2026

Pelican Acquisition Corp announced a Merger/Acquisition event via an 8-K filing on January 12, 2026 (AccNo: 0001829126-26-000189, Size: 271 KB), including Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on deal structure, parties involved, valuation, or financial terms are disclosed in the provided filing metadata. Sector is not specified.

12-01-2026

Katapult Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000950103-26-000342, Size: 253 KB) disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. No specific details on the key position affected, appointment or resignation, reasons, named individuals, or other impacts are provided. Sector is not specified.

12-01-2026

Rise Gold Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001062993-26-000154, Size: 240 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Telomir Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001170, Size: 206 KB), reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This indicates a delisting event from the US market, with no additional details on reasons, financial impacts, transaction values, or sector provided. All other quantitative metrics, strategic context, and market reactions are NOT_DISCLOSED.

12-01-2026

Edwards Lifesciences Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001099800-26-000002, Size: 203 KB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with no specific details on the disclosure content or attached exhibits provided. Sector is not specified.

12-01-2026

QXO, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002656, Size: 282 KB), disclosing Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on transaction values, parties, share counts, or financial impacts provided in the summary. Sector is not specified.

12-01-2026

Sensus Healthcare, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001753926-26-000088, Size: 215 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 lists financial statements and exhibits. No specific details on the affected officer, position, reason for change, or quantitative data provided in the filing summary.

12-01-2026

EACO CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002560, Size: 269 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, transaction values, percentages, or other quantitative financial metrics are mentioned in the provided filing summary. Sector is not specified.

12-01-2026

Inspire Veterinary Partners, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003112, size: 591 KB), reporting multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), and 9.01 (Financial Statements and Exhibits). Specific details including transaction values, parties, share counts, dollar amounts, strategic context, or financial impacts are NOT_DISCLOSED in the provided summary. Sector is not specified.

12-01-2026

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002691, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. This is a multi-item filing focused on financial results disclosure.

12-01-2026

Twin Vee PowerCats, Co. filed a Form 8-K on January 12, 2026 (AccNo: 0001731122-26-000038, Size: 190 KB) disclosing an event under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Sector is not specified. No specific details on positions, individuals, reasons, or quantitative data are provided in the filing summary.

12-01-2026

Hamilton Beach Brands Holding Co filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009679, Size: 2 MB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction values, or financial metrics are disclosed in the provided filing summary.

12-01-2026

Niocorp Developments Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001539497-26-000036, Size: 471 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Intuit Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000896878-26-000004, Size: 1 MB), disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. This is a multi-item mandatory filing with no specific transaction details, dollar values, or terms provided in the summary. Core event involves a material agreement and new financial obligation.

12-01-2026

USANA Health Sciences Inc filed an 8-K on January 12, 2026 (AccNo: 0000896264-26-000005, size 177 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific revenue, earnings, or other metrics detailed in the provided information. Sector not specified.

12-01-2026

Venture Global, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002007855-26-000002, Size: 202 KB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or detailed outcomes are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

J.Jill, Inc. filed a Form 8-K on January 12, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). Accession Number: 0001193125-26-009691; File size: 259 KB. No specific details on the disclosed information, events, financials, or exhibits are provided in the filing summary.

12-01-2026

Duolingo, Inc. disclosed an Officer Change event via Form 8-K filed on 2026-01-12 (AccNo: 0001628280-26-001730, Size: 10 MB), covering Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer involved, nature of change (appointment/resignation), reasons, or financial metrics are provided in the summary. Sector is not specified.

12-01-2026

Kosmos Energy Ltd. filed a Form 8-K on January 12, 2026, disclosing information under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001509991-26-000005 and a size of 190 KB. No specific details on events, transactions, financial impacts, or exhibits are provided in the summary.

12-01-2026

WEX Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000891, Size: 1 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Regulation FD Disclosure under Item 7.01. No specific details on the affected officer, position, reason for change, or any quantitative data are provided in the summary. Sector is not specified.

12-01-2026

Enovis CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001206, Size: 7 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Zura Bio Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002688, Size: 7 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on the core event, transactions, financials, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Lindsay Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009690, Size: 171 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders), and Item 9.01 (Financial Statements and Exhibits). No specific details on positions affected, reasons for change, voting outcomes, or exhibits are provided. Sector is not specified.

12-01-2026

UNITEDHEALTH GROUP INC filed a Form 8-K on January 12, 2026 (AccNo: 0000731766-26-000020, Size: 190 KB) reporting under Item 7.01 Regulation FD Disclosure. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Axsome Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009744, Size: 269 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure, but no specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. All detailed financial impacts, guidance, or events remain NOT_DISCLOSED.

12-01-2026

News Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001564708-26-000007, Size: 401 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing information. Sector not specified.

12-01-2026

Citi Trends Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002693, Size: 217 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with no sector specified. No core event details, financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

US Foods Holding Corp. filed an 8-K on January 12, 2026 (AccNo: 0001665918-26-000002, Size: 308 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific numerical financial metrics, transaction values, or other quantitative details provided in the filing summary. Event type is Financial Results from the US market, sector not specified.

12-01-2026

TriSalus Life Sciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001743, Size: 209 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

CareDx, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001217234-26-000007, Size: 192 KB), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. This is a financial results disclosure from the US market, sector not specified. No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary.

12-01-2026

Moderna, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001682852-26-000007, Size: 179 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure. No specific financial metrics, transaction values, or other numerical data are disclosed in the provided filing summary.

12-01-2026

Trinseo PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002698, Size: 256 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. Item 9.01 includes financial statements and exhibits. No specific details on positions, names, reasons, or quantitative data provided in the filing summary.

12-01-2026

Vince Holding Corp. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009731, Size: 10 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other specific information are disclosed in the filing summary. Sector is not specified.

12-01-2026

Uber Technologies, Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession Number: 0001543151-26-000005, File Size: 1 MB. No details on the specific event, transaction, or financial impacts are disclosed in the provided filing information.

12-01-2026

BioXcel Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002697, Size: 196 KB) under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are provided in the filing summary. Sector not specified.

12-01-2026

Annexon, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009740, Size: 176 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Karyopharm Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009738, Size: 314 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This appears to be a financial results announcement from the US market. No specific numerical data, transaction details, or further content from the filing is provided.

12-01-2026

Palvella Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009724, Size: 26 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with sector not specified. No specific details on events, transactions, financials, or exhibits are disclosed in the provided filing summary.

12-01-2026

Passage BIO, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002696, Size: 20 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Oxford Industries Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000199, size 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector not specified.

12-01-2026

IONIS PHARMACEUTICALS INC filed an 8-K on January 12, 2026 (AccNo: 0001140361-26-000893, Size: 209 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This appears to be a standard financial results disclosure.

12-01-2026

NovoCure Ltd filed a Form 8-K on January 12, 2026 (AccNo: 0001645113-26-000003, Size: 225 KB) reporting Item 2.02: Results of Operations and Financial Condition and Item 9.01: Financial Statements and Exhibits. This is a financial results disclosure from the US market, with sector not specified. No specific numerical financial metrics, transaction details, or further content from the filing is provided.

12-01-2026

Neurogene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001404644-26-000003, Size: 4 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary.

12-01-2026

Aclaris Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002694, Size: 12 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure with no core event, transaction details, financial metrics, or quantitative data explicitly stated in the provided filing summary. All specific numbers, impacts, and entities beyond the filer are NOT_DISCLOSED.

12-01-2026

XOMA Royalty Corp filed a Form 8-K on January 12, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with Accession No. 0001193125-26-009726 and file size 2 MB. No core event details, transaction values, financial metrics, or other specifics are disclosed in the provided filing information.

12-01-2026

OrthoPediatrics Corp filed an 8-K on January 12, 2026 (AccNo: 0001425450-26-000003, Size: 880 KB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, transaction values, percentages, or other quantitative financial metrics are disclosed in the provided filing summary. This is a multi-item filing focused on earnings disclosure with no details on outcomes or impacts.

12-01-2026

Neumora Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009727, Size: 5 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or attached exhibits are provided. Sector is not specified.

12-01-2026

Beam Therapeutics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009722, Size: 12 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results in the US equity market. No specific numerical data, transaction details, or financial metrics are disclosed in the provided filing summary.

12-01-2026

NewtekOne, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001749, Size: 927 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided summary. All quantitative data, named entities, and material impacts are NOT_DISCLOSED.

12-01-2026

Henry Schein Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009725, Size: 596 KB), disclosing an officer change event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), with Item 9.01 (Financial Statements and Exhibits). No specific details on positions affected, individuals involved, reasons for changes, or quantitative data are provided in the filing summary. Sector is not specified.

12-01-2026

Utz Brands, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001735), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US SEC. No specific financial metrics, transaction values, or detailed outcomes are provided in the filing summary.

12-01-2026

Fidelity National Information Services, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009759, Size: 241 KB), reporting the completion of an acquisition or disposition of assets under Item 2.01, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No details on parties involved, deal structure, valuation, or strategic rationale are explicitly stated. Sector not specified.

12-01-2026

BICYCLE THERAPEUTICS PLC filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002706, Size: 276 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the core event, transaction, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Global Payments Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002705, Size: 735 KB), disclosing under Item 1.01 entry into a material definitive agreement, Item 2.01 completion of an acquisition or disposition of assets, Item 3.02 unregistered sales of equity securities, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. This indicates a merger/acquisition event for Global Payments Inc. in the US market, but no specific parties, deal structure, valuation, or financial metrics are disclosed.

12-01-2026

Zumiez Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000201, Size: 219 KB), disclosing Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the Regulation FD disclosure or specific financial statements/exhibits are provided. Sector not specified.

12-01-2026

Agios Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, or numerical data disclosed in the provided filing summary. All quantitative metrics, named entities beyond the filer, and material impacts are NOT_DISCLOSED.

12-01-2026

Wave Life Sciences Ltd. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009784, size 20 MB), disclosing under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Axogen, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0000805928-26-000004, Size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or other quantitative data are mentioned.

12-01-2026

Neogenomics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001746, Size: 275 KB), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), and financial statements/exhibits (Item 9.01). Event type is Officer Change from US SEC source. No specific details on the officer position, appointment/resignation, reasons, or financial metrics are provided.

12-01-2026

European Wax Center, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009773, Size: 197 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, revenue, earnings, or other quantitative data are disclosed in the provided filing summary. This appears to be a standard earnings-related disclosure with no detailed content available.

12-01-2026

Sotera Health Co filed a Form 8-K on January 12, 2026 (AccNo: 0001822479-26-000004, Size: 504 KB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009758, Size: 22 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on voluntary disclosure of potentially material information and attached exhibits. No specific event details, financial metrics, or transaction information are disclosed in the provided filing summary.

12-01-2026

Brookdale Senior Living Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001332349-26-000004, Size: 786 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This constitutes a multi-item voluntary financial results disclosure. No specific financial metrics, transaction values, or detailed results are provided in the filing summary.

12-01-2026

Pegasystems Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001013857-26-000009, Size: 139 KB) reporting under Item 2.05 costs associated with exit or disposal activities. No specific dollar values, transaction details, named entities, or quantitative metrics were disclosed in the provided filing summary. This disclosure signals potential restructuring or cost-related events requiring materiality assessment.

12-01-2026

Portillo's Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001871509-26-000003, Size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure or the nature of the exhibits are disclosed in the filing summary. This is a voluntary disclosure under Regulation FD with no core event, transaction details, or financial metrics mentioned.

12-01-2026

Dyne Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009782, size: 16 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

Stoke Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009781, Size: 177 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a financial results announcement classified as an Event Type: Financial Results from the US market. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Dexcom Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001093557-26-000003, Size: 435 KB) under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, transaction values, or other quantitative metrics are disclosed in the provided filing summary. This is a routine earnings-related disclosure without detailed content available.

12-01-2026

Harvard Bioscience Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000203, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or other specifics are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure focused on Regulation FD.

12-01-2026

Summit Therapeutics Inc. filed an 8-K on January 12, 2026 (AccNo: 0001599298-26-000004, Size: 5 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market. No specific financial metrics, transaction details, or quantitative data are provided in the filing summary.

12-01-2026

Lyra Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009772), disclosing costs associated with exit or disposal activities under Item 2.05, departure of directors or certain officers, election/appointment of directors/officers, and compensatory arrangements under Item 5.02, and other events under Item 8.01. Event classified as Officer Change. No specific numerical values, names, reasons, or details provided in the summary.

12-01-2026

Ultragenyx Pharmaceutical Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009791, size 227 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

EDAP TMS SA filed a Form 8-K on January 12, 2026 (Accession No. 0001171843-26-000204, 9 MB), reporting results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a financial results disclosure event. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

TScan Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009771, size: 4 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Alnylam Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001755, size 235 KB) under Item 2.02 reporting results of operations and financial condition. This is a financial results disclosure for a US biotech company. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Avalo Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001534120-26-000003, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

InnovAge Holding Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001834376-26-000003, Size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure, financial statements, exhibits, transactions, or quantitative metrics are provided in the filing summary. This is a multi-item filing likely voluntary in nature.

12-01-2026

Krystal Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001711279-26-000008, Size: 171 KB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary financial results announcement. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.

12-01-2026

Emergent BioSolutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001367644-26-000003, Size: 210 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure related to Regulation FD.

12-01-2026

SunOpta Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001062993-26-000156, size 262 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

CERUS CORP filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009824, Size: 317 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a financial results disclosure from the US SEC. No specific revenue, earnings, transaction values, or other numerical financial metrics are mentioned.

12-01-2026

ProKidney Corp. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009807, Size: 16 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, financial metrics, transaction values, or other specifics are disclosed in the filing summary. Sector is not specified.

12-01-2026

Nuvation Bio Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009826, Size: 5 MB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, financial results, transaction values, or other quantitative data provided in the summary. All key transaction and financial metrics are NOT_DISCLOSED.

12-01-2026

BillionToOne, Inc. filed an 8-K on January 12, 2026 (AccNo: 0002070849-26-000010, size 159 KB), reporting Results of Operations and Financial Condition under Item 2.02 and Regulation FD Disclosure under Item 7.01. No specific financial metrics, transaction details, revenues, earnings, or guidance are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Vir Biotechnology, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001768, Size: 4 MB) under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific revenue, earnings, transaction values, or other quantitative metrics in the summary. No core event details, strategic impacts, or guidance changes are explicitly stated.

12-01-2026

Butterfly Network, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001804176-26-000002, Size: 201 KB) reporting Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector not specified.

12-01-2026

BioLife Solutions Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001767, Size: 365 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US market. No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary.

12-01-2026

SelectQuote, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001794783-26-000004, Size: 2 MB), reporting entry into a material definitive agreement (Item 1.01), termination of a material definitive agreement (Item 1.02), and creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing also includes Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). No specific transaction details, dollar values, or other quantitative data are disclosed.

12-01-2026

ADC Therapeutics SA filed a Form 8-K on January 12, 2026 (AccNo: 0000950103-26-000349, Size: 19 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with sector not specified. No core event details, financial metrics, transaction values, or other specifics are disclosed in the provided filing summary.

12-01-2026

MiMedx Group, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001376339-26-000003, size 3 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure content or exhibits are provided. This is a general filing from the US SEC with sector not specified.

12-01-2026

Akebia Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001517022-26-000003, Size: 4 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.

12-01-2026

Novavax Inc filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002725, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Noodles & Company filed an 8-K on January 12, 2026 (AccNo: 0001275158-26-000003, Size: 4 MB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Theravance Biopharma, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002726, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of potentially material non-public information with attached exhibits. Sector not specified; no specific event details, financial metrics, or transaction values disclosed in the provided summary.

12-01-2026

Catalyst Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). Accession Number: 0001193125-26-009822; File Size: 2 MB. No specific details on the disclosed information, events, transactions, financial metrics, or exhibits are provided in the filing summary.

12-01-2026

Cabaletta Bio, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009819, Size: 25 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

ABERCROMBIE & FITCH CO /DE/ filed a Form 8-K on January 12, 2026 (AccNo: 0001018840-26-000003), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing for material non-public information disclosure with attached exhibits. No core event details, transaction values, financial metrics, or other quantitative data are explicitly stated in the provided filing summary.

12-01-2026

ESTABLISHMENT LABS HOLDINGS INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001688757-26-000004, Size: 276 KB) under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a financial results disclosure with no specific revenue, earnings, or other quantitative metrics provided in the filing summary. Sector is not specified.

12-01-2026

Digi Power X Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003146, Size: 239 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the Regulation FD disclosure content or exhibits are provided in the filing summary. Sector not specified.

12-01-2026

Elanco Animal Health Inc filed a Form 8-K on January 12, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, core event, financial metrics, or transactions are provided in the filing summary. File size is 6 MB with Accession Number 0001104659-26-002723.

12-01-2026

Disc Medicine, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009871, Size: 15 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results with no specific numerical data, transaction details, or sector disclosed in the provided information. All quantitative financial metrics are NOT_DISCLOSED.

12-01-2026

Erasca, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009820, size: 17 MB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on events, transactions, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

AmpliTech Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001229, Size: 288 KB), disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are provided in the filing summary. Sector is not specified.

12-01-2026

Apyx Medical Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001048, Size: 208 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, transaction values, or other quantitative details are disclosed in the provided filing summary. This is a financial results announcement with attached exhibits, sector not specified.

12-01-2026

ONE Group Hospitality, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002722, Size: 248 KB), reporting Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided information.

12-01-2026

Galecto, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009812, size 16 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the Regulation FD disclosure content or exhibits are provided. Sector not specified.

12-01-2026

Bicara Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001766, Size: 301 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Alkermes plc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009813, Size: 14 MB) reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely related to earnings release or financial updates, but no specific financial metrics, transaction details, or other quantitative data are disclosed in the provided information. Sector is not specified.

12-01-2026

Planet Fitness, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001637207-26-000002, Size: 190 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No details on core events, transactions, financial impacts, or exhibits are disclosed in the provided summary. This appears to be a voluntary disclosure of potentially material information via Regulation FD.

12-01-2026

Oncology Institute, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001079973-26-000068, Size: 262 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This discloses financial results as a standard earnings-related filing. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.

12-01-2026

Protagonist Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002724, Size: 13 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the disclosures, events, transactions, or financial data are provided in the filing summary. Sector is not specified.

12-01-2026

Esperion Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001764, Size: 1 MB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a standard disclosure for financial results with no specific numerical data, transaction details, or outcomes provided in the filing summary. Sector is not specified.

12-01-2026

Strategy Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009811, Size: 374 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. No specific details on the core event, transaction, financial impacts, or quantitative data are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Digital Ally, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001493152-26-001231, Size: 671 KB), disclosing entry into a material definitive agreement (Item 1.01), completion of acquisition or disposition of assets (Item 2.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No specific details on parties, deal structure, valuation, or financial terms are provided in the filing summary. Sector not specified.

12-01-2026

Twist Bioscience Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001581280-26-000012, Size: 200 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This discloses financial results as a routine earnings-related filing. No specific financial metrics, transaction values, or quantitative details are provided in the filing summary.

12-01-2026

Adaptive Biotechnologies Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009840, size 8 MB), reporting Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

TransMedics Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009816, Size: 774 KB), reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the agreement, events, transaction value, or financial impacts disclosed in the provided information. All quantitative metrics such as dollar values, share counts, or percentages are NOT_DISCLOSED.

12-01-2026

CARLSMED, INC. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009828, Size: 178 KB) reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No quantitative financial metrics, transaction values, revenue, earnings, or other specific numbers are disclosed in the provided filing summary. This is a standard financial results disclosure with sector not specified.

12-01-2026

Kyverna Therapeutics, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009810, Size: 277 KB), disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election/appointment of directors/officers, or compensatory arrangements (Item 5.02), and financial statements/exhibits (Item 9.01). Specific details on the officer change, including position affected, appointment/resignation status, reasons, or any quantitative data, are NOT_DISCLOSED. No sector specified.

12-01-2026

Rigel Pharmaceuticals Inc filed an 8-K on January 12, 2026 (AccNo: 0001034842-26-000005, Size: 211 KB) reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market, sector not specified. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary.

12-01-2026

Replimune Group, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002721, Size: 5 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event details, transaction values, financial metrics, or other specifics are stated in the provided filing summary. All quantitative and material event data is NOT_DISCLOSED.

12-01-2026

Mind Medicine (MindMed) Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009854, Size: 14 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific financial metrics, transaction values, or detailed event descriptions provided in the summary. Analysis is limited to the disclosed item numbers.

12-01-2026

Senseonics Holdings, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002736, Size: 233 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data disclosed in the provided filing summary. Sector not specified.

12-01-2026

Hyperfine, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009859, Size: 7 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, with no specific revenue, earnings, transaction values, or other quantitative metrics provided in the summary. Sector is not specified.

12-01-2026

Bionano Genomics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000904, Size: 202 KB), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. Event type is Financial Results from the US market, with sector not specified.

12-01-2026

Bakkt Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009830, Size: 1 MB), reporting multiple material events under Items 1.01 (Entry into Material Definitive Agreement), 1.02 (Termination of Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure/Election/Appointment of Directors/Officers; Compensatory Arrangements), 5.03 (Amendments to Articles/Bylaws), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements/Exhibits). This is a multi-item mandatory filing with no specific transaction details, values, names, or financial impacts disclosed. Core events involve agreement changes, equity sales, governance shifts, and disclosures, signaling potential strategic or operational transitions.

12-01-2026

Harmony Biosciences Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002731, size 7 MB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned in the provided filing summary.

12-01-2026

AtriCure, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009814, Size: 1 MB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory filing with no specific transaction details, dollar values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Figure Technology Solutions, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001230, Size: 253 KB) reporting financial results under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, transaction values, or other quantitative financial metrics are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Geron Corp filed a Form 8-K on January 12, 2026 (AccNo: 0000886744-26-000003, Size: 3 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on core events, transactions, financial metrics, or other specifics are provided in the filing summary. Sector is not specified.

12-01-2026

Turn Therapeutics Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003153, Size: 218 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing with no specific event details, transaction values, or financial metrics disclosed in the provided summary. Sector is not specified.

12-01-2026

Fulcrum Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009845, size: 15 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results. No specific financial metrics, transaction values, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

Progyny, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001551306-26-000009, Size: 165 KB) reporting Item 2.02: Results of Operations and Financial Condition as part of Financial Results. Sector is not specified. No specific financial metrics, transaction values, revenues, earnings, or other quantitative details are disclosed in the provided filing summary.

12-01-2026

ClearPoint Neuro, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009867, Size: 187 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure from the US SEC with no specific revenue, earnings, transaction values, or other quantitative metrics mentioned. Sector is not specified.

12-01-2026

CVRx, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002728), reporting multiple items: Entry into a Material Definitive Agreement (Item 1.01), Results of Operations and Financial Condition (Item 2.02), Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement (Item 2.03), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). No specific details, transaction values, financial metrics, or named entities beyond the filer are disclosed in the provided summary. All quantitative data and core event descriptions are NOT_DISCLOSED.

12-01-2026

Mirum Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001759425-26-000004, Size: 9 MB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific numerical data, transaction details, or financial metrics are mentioned in the provided filing summary.

12-01-2026

Mereo BioPharma Group plc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009829, Size: 14 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure as Items 7.01 and 8.01 are typically voluntary. No specific core events, transactions, financial metrics, or quantitative data are explicitly stated in the provided filing summary.

12-01-2026

Day One Biopharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009834, Size: 8 MB), disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item financial results announcement. No specific financial metrics, transaction values, or quantitative data are mentioned in the provided filing summary.

12-01-2026

Recursion Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001601830-26-000002, size: 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the content of the Regulation FD disclosure or the nature of the financial statements/exhibits are provided. Sector is not specified.

12-01-2026

ADMA Biologics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000906, size: 4 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative impacts are detailed in the provided filing summary.

12-01-2026

Petco Health & Wellness Company, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009852), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the filing summary. Sector is not specified.

12-01-2026

Prime Medicine, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001773, Size: 6 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, numerical values, or specific content from the disclosures are provided in the filing summary. Sector is not specified.

12-01-2026

Acumen Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001774, Size: 8 MB), under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or quantitative data are explicitly stated in the provided filing summary. This appears to be a voluntary disclosure of other events with attached exhibits.

12-01-2026

Kelly Services Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009849, Size: 231 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, modifications, or disclosures provided in the available summary. All transaction values, financial metrics, and other quantitative data are NOT_DISCLOSED.

12-01-2026

Myriad Genetics Inc filed a Form 8-K on January 12, 2026 (AccNo: 0000899923-26-000003), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing financial results. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary.

12-01-2026

Nurix Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001549595-26-000003, size 5 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure under Regulation FD.

12-01-2026

Perspective Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009846, Size: 285 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. No quantitative data, named entities beyond the filer, or material impacts are mentioned.

12-01-2026

Amprius Technologies, Inc. filed a Form 8-K on January 12, 2026, reporting under Item 8.01 Other Events. Accession number: 0001899287-26-000003; file size: 185 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.

12-01-2026

GLOBAL PARTNERS LP filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002740, Size: 343 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a general filing with no specific core event, transaction details, financial metrics, or numerical values disclosed in the provided summary. Sector is not specified.

12-01-2026

Allegiant Travel Co filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000907, Size: 8 MB), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, disclosures, or financials provided in the summary. Sector not specified.

12-01-2026

Autolus Therapeutics plc filed a Form 8-K on January 12, 2026 (AccNo: 0001730463-26-000012, Size: 7 MB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on the events, transactions, financials, or exhibits are disclosed in the provided filing summary. Sector not specified.

12-01-2026

Quantum Computing Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003174, Size: 220 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financials provided in the summary. Sector not specified.

12-01-2026

Heartflow, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001464521-26-000005, Size: 10 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US market with sector not specified. No core event details, financial data, or transaction specifics are disclosed in the provided filing summary.

12-01-2026

Septerna, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009864, Size: 14 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Moleculin Biotech, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001050, Size: 227 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific core event, transaction details, financial metrics, or numerical values disclosed in the provided summary. Sector is not specified.

12-01-2026

MACOM Technology Solutions Holdings, Inc. disclosed an Officer Change via Form 8-K filed on January 12, 2026 (AccNo: 0001493594-26-000002, Size: 207 KB). The filing covers Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer, position, reason for change, or quantitative data are provided in the summary.

12-01-2026

OS Therapies Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001213900-26-003166, Size: 468 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction values, share counts, dollar amounts, named parties, or financial metrics disclosed in the provided information. All quantitative details such as transaction value, share count, and percentage changes are NOT_DISCLOSED.

12-01-2026

Outset Medical, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009865, Size: 7 MB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements), alongside Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position (e.g., CEO, CFO), nature of change (appointment or resignation), reasons, or financial metrics are disclosed. All quantitative data such as transaction values, share counts, or percentages is NOT_DISCLOSED.

12-01-2026

Sonoma Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001683168-26-000205, Size: 8 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Clene Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001437749-26-001049, Size: 195 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the provided filing summary. Sector is not specified.

12-01-2026

Sadot Group Inc. filed an 8-K on January 12, 2026 (AccNo: 0001731122-26-000046, Size: 191 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No additional details on the core event, reasons, financial impacts, or quantitative metrics are provided in the filing summary. Sector is not specified.

12-01-2026

Microbot Medical Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001234, Size: 246 KB) under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial statements, or exhibits are disclosed in the provided filing summary.

12-01-2026

Aardvark Therapeutics, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009862, Size: 11 MB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, or financial statements are provided in the filing summary. Sector not specified.

12-01-2026

Tarsus Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001819790-26-000002, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing focused on disclosing material non-public information and attaching exhibits. No specific event details, financial metrics, or transaction values are disclosed in the provided filing summary.

12-01-2026

Amphenol Corp (/DE/) filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002737, Size: 252 KB) disclosing the completion of an acquisition or disposition of assets under Item 2.01. The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No details on deal structure, parties, valuation, or strategic rationale are explicitly stated.

12-01-2026

Inogen Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009878, Size: 186 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results announcement from the US market. No specific financial metrics, transaction values, or quantitative details are disclosed in the provided filing summary.

12-01-2026

VisionWave Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001731122-26-000045, Size: 398 KB), reporting under Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. Sector not specified. No details on the agreement, transaction value, parties, or exhibits provided in the summary.

12-01-2026

CRISPR Therapeutics AG filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009880, Size: 167 KB) reporting under Item 8.01: Other Events. No details on the specific event, transaction, financial impacts, or quantitative metrics are disclosed in the provided filing summary. All numerical values, named entities beyond the filer, and material event specifics are NOT_DISCLOSED.

12-01-2026

BITMINE IMMERSION TECHNOLOGIES, INC. filed a Form 8-K on January 12, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing has Accession Number 0001493152-26-001237 and a file size of 254 KB. No specific details on the content of the disclosure, financials, or exhibits are provided in the summary.

12-01-2026

Ondas Holdings Inc. filed Form 8-K on 2026-01-12 (AccNo: 0001213900-26-003169, Size: 1 MB) reporting Items 1.01 (Entry into a Material Definitive Agreement), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with Item 1.01 being mandatory disclosure of a material event. No specific details, transaction values, or financial metrics are disclosed in the provided filing summary.